Last Update 08 Jul 26
Fair value Increased 8.70%SY1: Downgrade Signals Future Pressure From Weaker Demand And Input Costs
Analysts have lifted the fair value estimate for Symrise to €75.00, reflecting updated views on revenue growth, profit margins and valuation multiples following recent research. This includes a higher €98.00 price target and a separate downgrade to Neutral with an unchanged €79.00 target.
Analyst Commentary
Recent research on Symrise reflects a mix of confidence and caution, with some firms lifting price targets while others are turning more reserved. For you as an investor, the key takeaway is that analysts are not aligned on how much upside is left in the stock at current levels.
On the positive side, one major bank has set a higher €98.00 price target while maintaining a supportive stance on Symrise. This signals that some analysts still see room for the company to justify a higher valuation, based on their assumptions for revenue growth, margins and execution against its strategy.
However, not all research is pointing in the same direction. A separate call from Goldman Sachs downgraded Symrise to Neutral with an unchanged €79.00 target. That shift in rating, despite a steady target, highlights growing caution around how the company might handle weaker demand and pressure on input costs.
For investors, the gap between the higher €98.00 target and the more cautious €79.00 target underlines how differently Symrise's risk and reward profile is being assessed. The range of views largely turns on expectations for profitability, pricing power and the resilience of end markets.
Bearish Takeaways
- Bearish analysts point to the Neutral rating at €79.00 as a sign that some see limited upside from current levels, with valuation already reflecting a fair amount of optimism about Symrise's execution.
- Concerns around a potential downturn in European chemicals lead cautious analysts to question how Symrise will manage weaker demand and higher input costs without putting pressure on margins.
- The focus on "defensive pricing power picks" signals a preference for companies viewed as better positioned to pass through cost inflation, which some bearish analysts see as a relative risk for Symrise.
- The split between a higher €98.00 target and the unchanged €79.00 target highlights uncertainty around Symrise's medium term growth path and consistency of earnings, which can cap how much some investors are willing to pay for the stock.
What’s in the News for Symrise
- No recent company specific news items for Symrise are available from the provided sources at this time.
- Analyst research, including revised fair value and price targets, currently represents the main publicly referenced information on Symrise.
- Investors who monitor news flow for Symrise may want to focus on upcoming company disclosures or future research reports as new information becomes available.
Valuation Changes for Symrise
- Fair Value: updated from €69.00 to €75.00, a rise of around 9% in the modelled fair value for Symrise.
- Discount Rate: adjusted slightly lower from 5.65% to 5.64%, a small change in the rate used to discount future cash flows.
- Revenue Growth: revised from 2.66% to 3.23%, indicating modestly higher assumed euro revenue growth in the model.
- Net Profit Margin: moved from 10.56% to 12.32%, reflecting a higher assumed level of future euro profitability.
- Future P/E: reduced from 19.91x to 18.53x, indicating a slightly lower earnings multiple applied to Symrise in the updated valuation.
Catalysts
About Symrise
Symrise develops and manufactures flavors, fragrances, and functional ingredients for food, pet care, personal care, and health applications worldwide.
What are the underlying business or industry changes driving this perspective?
- Although Symrise is executing on a sizable cost saving and efficiency agenda, the increasing reliance on self help to lift margins risks reaching a ceiling if raw material and logistics markets tighten again. This could cap future EBITDA expansion and slow earnings growth.
- While global demand for science based health, wellness and metabolic solutions is rising, a more moderate market growth outlook and tougher prior year comparables may limit the pace at which innovations like Metabolic Health by Probi translate into sustained top line acceleration and higher revenue.
- Although pet ownership and premiumization remain supportive long term, ongoing price pressure and normalization in Pet Nutrition suggest that mix could shift toward lower value offerings. This would weigh on segment profitability and constrain group net margin improvement.
- Despite portfolio pruning in Aqua Feed and Terpene Ingredients, a sharper focus on high margin, lower capital intensity niches could also reduce diversification. This could leave Symrise more exposed to volatility in core categories such as Fine Fragrance and beverages and thereby increase earnings variability.
- While the One Symrise transformation and global procurement initiatives are improving gross margin and cash generation, the need to reinvest a meaningful share of identified savings into digitalization, R&D and commercial capabilities may delay visible operating leverage. This could limit near term expansion in free cash flow and EPS.
Assumptions
How have these above catalysts been quantified?
- This narrative explores a more pessimistic perspective on Symrise compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.
- The bearish analysts are assuming Symrise's revenue will grow by 3.2% annually over the next 3 years.
- The bearish analysts assume that profit margins will increase from 5.1% today to 12.3% in 3 years time.
- The bearish analysts expect earnings to reach €668.2 million (and earnings per share of €4.54) by about July 2029, up from €249.3 million today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as €740.9 million.
- In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 18.5x on those 2029 earnings, down from 50.2x today. This future PE is lower than the current PE for the GB Chemicals industry at 24.5x.
- The bearish analysts expect the number of shares outstanding to grow by 0.08% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 5.64%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?
- The multiyear ONE SYM Transformation, which is already driving a 250 basis point improvement in gross margin and EUR 40 million of 2025 cost savings, could continue to compound efficiencies and mix upgrades, leading to sustained EBITDA margin expansion above the current 21.7% and boosting earnings and free cash flow over time.
- Symrise is reaffirming midterm organic compounded annual growth of 5% to 7% and targeting business free cash flow of more than 14% of sales, so a cyclical demand recovery from the currently moderated 2% to 3% market growth, combined with its above market positioning, could accelerate revenue growth and push earnings higher than implied by a flat share price view.
- Portfolio optimization through divestments in Aqua Feed and Terpene Ingredients, and a sharper focus on high margin, low capital intensity niches, may structurally lift the group margin profile and capital efficiency, improving net margins and returns on invested capital in a way that supports a rerating of the equity.
- Long term secular demand for science based health, wellness and metabolic solutions, together with a growing innovation ecosystem including launches like Metabolic Health by Probi and the build out of the One Care division, could translate into faster growth in Taste, Nutrition & Health and Scent & Care, driving higher revenue and structurally stronger earnings.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The assumed bearish price target for Symrise is €75.0, which represents up to two standard deviations below the consensus price target of €94.62. This valuation is based on what can be assumed as the expectations of Symrise's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
- However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of €110.0, and the most bearish reporting a price target of just €75.0.
- In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be €5.4 billion, earnings will come to €668.2 million, and it would be trading on a PE ratio of 18.5x, assuming you use a discount rate of 5.6%.
- Given the current share price of €90.94, the analyst price target of €75.0 is 21.3% lower. Despite analysts expecting the underlying business to improve, they seem to believe the market's expectations are too high.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on Symrise?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
AnalystLowTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystLowTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystLowTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
